Leadership & Pay ·
Tango Therapeutics, Inc. expanded its Board of Directors to seven members on June 19, 2026, with the appointment of…
TNGXTango Therapeutics, Inc.
Tango Therapeutics, Inc. expanded its Board of Directors to seven members on June 19, 2026, with the appointment of Robert Azelby. Mr. Azelby will serve as a Class II director and join the Compensation and Nominating and Corporate Governance Committees effective June 23, 2026. His compensation includes an annual retainer of $45,000 for board service, $7,500 for compensation committee service, and $5,000 for governance committee service. Additionally, he received an equity award comprising 35,910 stock options at an exercise price of $27.97 and 5,740 restricted stock units. Tango Therapeutics, Inc. is a biotechnology company focused on developing precision medicines.